Skip to main content

Ocugen, Inc.

OCGN
Exchange
Nasdaq
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001372299

In the last 90 days, Ocugen, Inc. insiders filed 0 open-market purchases and 1 sale; 147 institutions reported holding it in 13F filings for Q2 2026, worth $222.1M in total; no superinvestor holds it.

Q4 2023 vs. Q3 2023

How the institutions holding Ocugen, Inc. changed between Q3 2023 and Q4 2023.

All holders in Q4 2023All holders in Q3 2023

13F holders of OCGN: Q3 2023 compared with Q4 2023
MeasureQ3 2023Q4 2023Change
Holders7868−10
Shares33.0M26.3M−6.76M (−20.5%)
Value$13.2M$15.1M+$1.89M (+14.3%)

New holders (11)

Institutions that held Ocugen, Inc. at the end of Q4 2023 but not at the end of Q3 2023.

Institutions new to OCGN in Q4 2023
InstitutionSharesValue% of portfolio
Gsa Capital Partners LLP58,120$33.0K0.00%
Point72 Asia (Singapore) Pte. Ltd.25,800$14.8K0.00%
XTX Topco Ltd24,702$14.2K0.00%
Cetera Advisor Networks LLC20,300$11.7K0.00%
Wedmont Private Capital14,765$9.60K0.00%
Lanham O'Dell & Company, Inc.11,050$6.35K0.00%
GTS Securities LLC10,923$6.28K0.00%
Retirement Group, LLC9,910$5.70K0.00%
Vima LLC365$2100.00%
Advisory Services Network, LLC270$1550.00%
Johnson Financial Group, Inc.1$10.00%

Sold out (21)

Institutions that held Ocugen, Inc. at the end of Q3 2023 and filed for Q4 2023 without it.